Page 7 - வணிகமயமாக்கல் ஆஃப் தொழில்நுட்பம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வணிகமயமாக்கல் ஆஃப் தொழில்நுட்பம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வணிகமயமாக்கல் ஆஃப் தொழில்நுட்பம் Today - Breaking & Trending Today

BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix (eslicarbazepine acetate), Expanding Neurology Footprint

(2)
Press Release for European Medical and Trade Media Only
BIAL announces the end of the licence agreement established in 2009. BIAL takes the lead for the marketing and distribution of Zebinix
(eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures)
For over a decade, BIAL and Eisai have had an agreement in place for Eisai to market, promote, and distribute eslicarbazepine acetate in Europe. Following the end of this partnership, BIAL will take the lead for the ongoing marketing, promotion and distribution in Europe. This move reinforces its continued commitment to and ongoing investment in neurological conditions. ....

Susana Vasconcelos , Almeida Bastos , Biochem Biophys , Kostenloser Wertpapierhandel , Chrissie Hartgill , Makara Health , World Health Organization , Health Press , Press Release , European Medical , Trade Media , Chief Commercial Officer , Vice President , Global Neurology Business Unit , Fostering Epilepsy Care , Last Accessed January , World Health Organization Report , Nat Rev Dis Primers , United Kingdom , Health Press Limited , சுசானா வாஸ்கான்செலோஸ் , அல்மேடா பாஸ்டோஸ் , மகர ஆரோக்கியம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , ஆரோக்கியம் ப்ரெஸ் , ப்ரெஸ் வெளியீடு ,

Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for treatment of Plaque Psoriasis

(1)
In this collaboration Almirall will commercialize Wynzora
Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
MC2 Therapeutics and Almirall partner to make Wynzora Cream a leading topical product for Plaque Psoriasis in Europe
In a large European based Phase 3 clinical trial (n=490), Wynzora
Cream has demonstrated substantial efficacy with a PGA treatment success of 51% and beneficial treatment convenience
1
Cream has been filed and approval is expected this year
Almirall S.A. (BME: ALM), a global biopharmaceutical company and
MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora ....

Comunidad Autonoma De Cataluna , Dovobet Daivobet , Susanne Andersen Fitch , Omar Ram , Jesperj Lange , Almirall Corporate Communications , Corporate Communications , Therapeutics Group , Spanish Stock Exchange , Wynzora Cream , Plaque Psoriasis , Authorization Application , Physician Global Assessment , Noble Purpose , காமுனிடட தன்னாட்சி டி கடலுள் , ஸூஸந் ஆண்டர்சன் ஃபிட்ச் , மார் ரேம் , பெருநிறுவன தகவல்தொடர்புகள் , சிகிச்சை குழு , ஸ்பானிஷ் ஸ்டாக் பரிமாற்றம் , தகடு தடிப்புத் தோல் அழற்சி , அங்கீகாரம் விண்ணப்பம் , மருத்துவர் உலகளாவிய மதிப்பீடு , உன்னத நோக்கம் ,

Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast

NEW YORK, Feb. 17, 2021 Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system . | February 21, 2021 ....

Lisa Burns , Juan Sanchez , Cellular Therapies Inc , Corporate Communications , Burns Mcclellan Inc , Cellular Therapies , Investor Relations , Intra Cellular Therapies , Inc Stock Exchange , Press Release , System Itci , லிசா தீக்காயங்கள் , ஜுவான் சான்செஸ் , செல்லுலார் சிகிச்சைகள் இன்க் , பெருநிறுவன தகவல்தொடர்புகள் , தீக்காயங்கள் ம்க்க்லெல்யாந் இன்க் , செல்லுலார் சிகிச்சைகள் , முதலீட்டாளர் உறவுகள் , இன்ட்ரா செல்லுலார் சிகிச்சைகள் , இன்க் ஸ்டாக் பரிமாற்றம் , ப்ரெஸ் வெளியீடு ,

Fidelity Leads $81M Investment in Enevate to Accelerate Commercialization of Fast-Charging Electric Vehicle Battery Technology

Fidelity Leads $81M Investment in Enevate to Accelerate Commercialization of Fast-Charging Electric Vehicle Battery Technology
Advances Silicon Anode Cell Technology for EVs
Enevate, a pioneer in advanced silicon-dominant lithium-ion (Li-ion) battery technology featuring extreme fast charge and high energy density for electric vehicles (EVs) and other markets, announced that it has secured a $81M Series E funding led by Fidelity Management Research Company, providing the company with additional new resources aimed at accelerating global mass adoption of Enevate s unique battery technology in electric vehicles. Existing investors, Mission Ventures and Infinite Potential Technologies, also participated in the round.
Enevate said that the investment would enable the company to significantly expand its pre-production line designed to guide EV and other battery customers toward implementing larger-scale battery manufacturing utilizing Enevate s silicon anode-based batt ....

United States , Roberta Rango , Kostenloser Wertpapierhandel , Enevate Corporation , Samsung Venture Investment Corporation , Draper Fisher Jurvetson , Samsung Venture Investment Corp , Lg Energy Solutions , Presidio Venturesa Sumitomo Corporation , Fidelity Management Research Company , Alliance Ventures , Mission Ventures , Advances Silicon Anode Cell Technology , Infinite Potential Technologies , Hadi Zablit , Sungrok Bang , Open Innovation , Samsung Venture Investment , Tsing Capital , Presidio Ventures , Sumitomo Corporation , ஒன்றுபட்டது மாநிலங்களில் , ரோபர்ட்டா ரங்கோ , சாம்சங் துணிகர முதலீடு நிறுவனம் , சாம்சங் துணிகர முதலீடு கார்ப் , எல்ஜி ஆற்றல் தீர்வுகள் ,

PCG Digital: Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301

(3)
New York, New York (Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company s plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL).
Here are some key takeaways from the commercialization Q&A:
1. Soligenix will commercialize SGX301 in the U.S. on its own
During the presentation, the company noted that after conducting necessary due diligence and simulating different routes to commercialization, it was determined that a partnership would not be the best solution for shareholders. The licensing landscape and CTCL s small, orphan market were the key drivers behind the decision. Considering that the average biopharmaceutical licensing deal, a Phase 3 licensor will typically retain no more than 40 ....

New York , United States , Chris Schaber , Jonathan Guarino , Zack Research Updates Soligenix , York Newsfile Corp , Cap Research , Advisory Inc , Digital Holdings , Multiple Near Term Catalysts Anticipated , New Drug Application , Clinical Study Report , Prescription Drug User Fee Act , American Academy , Dermatology Meeting , Investigative Dermatology Meeting , Research Updates Soligenix , Positive Report , Small Cap Research , Paid Advertising , Securities Act , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ் ஸ்கேபர் , ஜொனாதன் குவாரினோ , தொப்பி ஆராய்ச்சி ,